Methods for producing cells having a phenotype of a primary human hepatocytes and compositions

Patent metadata

Field	Value
Publication number	US-9969979-B2
Application number	US-201314423991-A
Country	US
Kind code	B2
Filing date	Aug 30, 2013
Priority date	Aug 31, 2012
Publication date	May 15, 2018
Grant date	May 15, 2018

Abstract

The present disclosure provides methods and compositions relating to in vitro cultures of human hepatocyte cell lines which exhibit a primary human hepatocyte phenotype. Such cell lines are susceptible to infection by a hepatotrophic virus, such as HCV or HBV, and support both viral replication and high levels of viral particle production. Such in vitro cultures find use in production and study of hepatotrophic virus, as well as methods of screening (e.g., for antiviral drugs, assessing drug metabolism), and study of primary human hepatocytes.

First claim

What is claimed is:

1. A method of producing a cell culture comprising cells having a primary human hepatocyte phenotype, the method comprising:
culturing a human hepatocellular carcinoma (hHCC) cell line in a culture medium comprising human serum for more than 11 days,
wherein said culturing is without subculturing after 10 days of culturing in the culture medium comprising human serum,
wherein said culturing does not comprise transforming the hHCC cell line, and
wherein said culturing induces differentiation of the hHCC cell line into a cell having a primary human hepatocyte phenotype.

2. The method of claim 1 , wherein the culture medium comprises about 1% to 20% human serum.

3. The method of claim 1 , wherein the culture medium comprises about 2% to 10% human serum.

4. The method of claim 1 , wherein the hHCC cell line is a HuH-7 or HuH-7-derived cell line.

5. The method of claim 1 , wherein the culturing comprises culturing the hHCC cell line in the culture medium comprising human serum for more than 14 days.

6. The method of claim 1 , wherein the culturing comprises culturing the hHCC cell line in the culture medium comprising human serum for more than 21 days.

7. The method of claim 1 , further comprising assessing an effect of a candidate agent on the cell having a phenotype of a human primary hepatocyte, the method comprising:
contacting the cell having a primary human hepatocyte phenotype with a candidate agent; and
assaying for the presence or absence of an effect of the candidate agent on a phenotype of the cell having a phenotype of a human primary hepatocyte.

8. The method of claim 7 , wherein said assaying is for an effect of the candidate agent on lipid metabolism by the cell having a phenotype of a primary human hepatocyte.

9. The method of claim 7 , wherein said assaying is for an effect of the candidate agent on very low density lipoprotein (VLDL), low density lipoprotein (LDL), and/or high density lipoprotein (HDL) secretion by the cell having a phenotype of a primary human hepatocyte.

10. The method of claim 1 , further comprising assessing metabolism of an agent by the cell having a phenotype of a human primary hepatocyte, the method comprising:
contacting the cell having a primary human hepatocyte phenotype with an agent; and
assaying for the presence of absence of a metabolite of the agent and/or the agent.

11. The method of claim 10 , wherein the agent is a drug.

12. The method of claim 1 , further comprising assessing toxicity of an agent on the cell having a phenotype of a human primary hepatocyte, the method comprising:
contacting the cell having a primary human hepatocyte phenotype with an agent; and
assaying for the presence or absence of a change in a phenotype of the cell which is indicative of toxicity of the agent for the cell.

13. The method of claim 12 , wherein the phenotype is an increase in transaminase in culture medium.

14. The method of claim 12 , wherein the phenotype is an increase in a marker of cell death.

15. A method of producing viral particles, the method comprising:
incubating a cell culture comprising a human hepatocellular carcinoma (hHCC) cell line in a culture medium comprising human serum for more than 11 days,
wherein said incubating is without subculturing after 10 days of culturing in the culture medium comprising human serum,
wherein said incubating does not comprise transforming the hHCC cell line,
wherein said incubating induces differentiation of the hHCC cell line into a cell having a primary human hepatocyte phenotype;
introducing a genome of a hepatotrophic virus into the cell having primary human hepatocyte phenotype; and
maintaining the cell culture under conditions suitable for production of viral particles.

16. The method of claim 15 , wherein said introducing is by adding infectious viral particles to the culture medium.

17. The method of claim 15 , wherein said introducing is by infection of the hepatotrophic virus and the cell culture comprises lipoprotein-depleted serum.

18. The method of claim 15 , wherein the method comprises isolating viral particles from the culture medium.

19. A method for screening a candidate agent for antiviral activity, the method comprising:
incubating a cell culture comprising a human hepatocellular carcinoma (hHCC) cell line in a culture medium comprising human serum for more than 11 days, wherein said incubating is without subculturing after 10 days of culturing in the culture medium comprising human serum wherein said incubating does not comprise transforming the hHCC cell line, wherein said incubating induces differentiation of the hHCC cell line into a cell having a primary human hepatocyte phenotype;
introducing a genome of a hepatotrophic virus into the cell having primary human hepatocyte phenotype;
contacting the cell culture with a candidate antiviral agent;
maintaining the cell culture under conditions suitable for viral replication; and
detecting the presence or absence of an effect of the candidate agent upon viral replication;
wherein a decrease in viral particle production in the presence of the candidate agent as compared to the absence of the candidate agent indicates the candidate agent have antiviral activity.

20. The method of claim 19 , wherein said introducing is by adding infectious viral particles to the culture medium.

21. A method for screening a sample suspected of containing an antibody for antiviral activity, the method comprising:
incubating a cell culture comprising a human hepatocellular carcinoma (hHCC) cell line in a culture medium comprising human serum for more than 11 days, wherein said incubating is without subculturing after 10 days of culturing in the culture medium comprising human serum wherein said incubating does not comprise transforming the hHCC cell line, wherein said incubating induces differentiation of the hHCC cell line into a cell having a primary human hepatocyte phenotype;
introducing a genome of a hepatotrophic virus into the cell having primary human hepatocyte phenotype;
contacting the cell culture with a sample of suspected of containing an antibody;
maintaining the cell culture under conditions suitable for viral replication; and
detecting the presence or absence of an effect of the sample upon viral replication;
wherein a decrease in viral particle production in the presence of the sample as compared to the absence of the sample indicates the sample contains an antibody having antiviral activity.

22. The method of claim 21 , wherein said introducing is by adding infectious viral particles to the culture medium.

23. The method of claim 1 , further comprising screening for a candidate agent for the treatment of a lipoprotein mediated disease, the method comprising:
contacting a cell culture comprising the cell having a primary human hepatocyte phenotype with the candidate agent; and
assaying the cell culture for the presence or absence of an effect of the candidate agent on the levels of lipoprotein secreted by the cell having a primary human hepatocyte phenotype as compared to a control sample;
wherein an effect of the candidate agent on the levels of lipoprotein secreted by the cell having a primary human hepatocyte phenotype indicates that the candidate agent can be used for the treatment of the lipoprotein mediated disease.

24. The method of claim 23 , wherein the cell culture is assayed for the presence or absence of an effect of the

Assignees

• Univ Alberta

Inventors

• Tyrrell D Lorne
• Steenbergen Hendrikje Geesje
• Joyce Michael A

Classifications

• G01N33/5014

  for testing toxicity · CPC title

• C12N2506/30

  from cancer cells, e.g. reversion of tumour cells · CPC title

• C12N5/067 Primary

  Hepatocytes · CPC title

• G01N33/5026

  on cell morphology · CPC title

• C12N2770/24252

  relating to complementing cells and packaging systems for producing virus or viral particles · CPC title